This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove HIV Treatment and Prevention Agents Remove Packaging Remove Presentation Related Topics
Dosage Documentation Pharmaceutical Companies Immunization Vaccines FDA Pharmaceutical Companies More Related Topics >
article thumbnail

Top 20 RNAi Therapeutic Companies Based on 2022 R&D Expenditure

PharmaShots

APRIL 25, 2023

This year Roche has secured the top position with a total R&D Expenditure of $15.20B, followed by Johnson & Johnson and AstraZeneca PharmaShots presents the Top 20 RNAi therapeutic companies based on their R&D Expenditure in the year 2022 R&D Expenditure: $43.1M R&D Expenditure: $85.1M R&D Expenditure: $437.9M

HIV Treatment and Prevention Agents 40
HIV Treatment and Prevention Agents Packaging Immunization Vaccines 40
article thumbnail

Agile, Data-Driven Life Cycle Management for Continuous Manufacturing

ISPE

JULY 6, 2023

1 , 4 A Retrospective Journey In 2015, Vertex’s Orkambi was the first approved drug produced under a CM process for the treatment of cystic fibrosis. Operational Flexibility/Capacity Decentralized manufacturing Presently, portable end-to-end CM plants are not a widespread reality, but have been proven possible.

HIV Treatment and Prevention Agents 52
HIV Treatment and Prevention Agents Dosage Pharmaceutical Companies Pharmaceutical Companies 52
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 18,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024